{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:14:26Z","timestamp":1771931666275,"version":"3.50.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-marketing surveillance has documented cardiovascular adverse events following COVID-19 vaccination, including acute myocardial infarction (AMI); however, evidence regarding causal associations remains contradictory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether a causal association exists between nucleic acid-based COVID-19 vaccines (mRNA and DNA platforms) and AMI in adults aged 18\u201380 years<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review following PRISMA 2020 guidelines searched PubMed, Cochrane CENTRAL, and Google Scholar for studies evaluating mRNA vaccines (Pfizer-BioNTech, Moderna) and DNA-based vaccines (AstraZeneca) with AMI as primary outcome. Quality assessment used the Newcastle-Ottawa Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine studies from 16 countries were analyzed, including 14 population-based cohorts (&amp;gt;142.5 million individuals, &amp;gt;130,000 AMI cases), 12 case reports (54 AMI events), and three pharmacovigilance studies. Large cohorts demonstrated no significant association between nucleic acid vaccines and AMI. A Swedish study (8.1 million) showed protective effects (HR: 0.81; 95% CI: 0.74\u20130.89 for third dose). A Malaysian study (22.2 million) found no significant increase after BNT162b2 (dose 1 IRR: 0.97; dose 2 IRR: 1.08) or ChAdOx1 (dose 1 IRR: 1.02; dose 2 IRR: 1.58). Case reports documented temporal associations but had substantial methodological limitations. Quality assessment revealed low-to-moderate bias in population studies but high bias in case reports and pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-quality population-based evidence from 14 independent cohorts does not support a causal association between nucleic acid-based COVID-19 vaccines and AMI. Case reports lack the methodological rigor to establish causality. The documented protective effects after booster doses and consistency across diverse populations demonstrate vaccine cardiovascular safety, supporting continued vaccination policies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1752169","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:15:06Z","timestamp":1770880506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between nucleic acid COVID-19 vaccines and acute myocardial infarction in adults: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Dalia I.","family":"Castellanos-Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Laboratorio de Bioqu\u00edmica, Facultad de Medicina y Cirug\u00eda, Universidad Aut\u00f3noma Benito Ju\u00e1rez de Oaxaca, Ex Hacienda de Aguilera S\/N, Sur","place":["San Felipe del Agua, Oaxaca, M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Mayoral-Ch\u00e1vez","sequence":"additional","affiliation":[{"name":"Laboratorio de Bioqu\u00edmica, Facultad de Medicina y Cirug\u00eda, Universidad Aut\u00f3noma Benito Ju\u00e1rez de Oaxaca, Ex Hacienda de Aguilera S\/N, Sur","place":["San Felipe del Agua, Oaxaca, M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Matias-Cervantes","sequence":"additional","affiliation":[{"name":"SECIHTI- Facultad de Medicina y Cirug\u00eda, Universidad Aut\u00f3noma Benito Ju\u00e1rez de Oaxaca, Ex Hacienda de Aguilera S\/N, Sur","place":["San Felipe del Agua, Oaxaca, M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Alpuche","sequence":"additional","affiliation":[{"name":"Laboratorio de Bioqu\u00edmica, Facultad de Medicina y Cirug\u00eda, Universidad Aut\u00f3noma Benito Ju\u00e1rez de Oaxaca, Ex Hacienda de Aguilera S\/N, Sur","place":["San Felipe del Agua, Oaxaca, M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","author":"Adhanom-Ghebreyesus","year":"2020"},{"key":"B2","year":"2023"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.imu.2024.101564","article-title":"Evaluation of the effects of MERCK, MODERNA, PFIZER\/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: a metadata analysis","volume":"49","author":"Al-Rousan","year":"2024","journal-title":"Inform Med Unlocked"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2022","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1016\/j.vaccine.2023.06.014","article-title":"Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: two self-controlled studies in the U.S","volume":"41","author":"Shoaibi","year":"2023","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104362","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: cOVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J Clin Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e069590","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study","volume":"377","author":"Katsoularis","year":"2022","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","article-title":"Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales","volume":"146","author":"Knight","year":"2022","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1003926","DOI":"10.1371\/journal.pmed.1003926","article-title":"Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England","volume":"19","author":"Whiteley","year":"2022","journal-title":"PLoS Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/eurheartj\/ehae639","article-title":"Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study","volume":"46","author":"Xu","year":"2025","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMC2302134","article-title":"Myocardial infarction, and pulmonary embolism after bivalent booster","volume":"388","author":"Jabagi","year":"2023","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e245218","DOI":"10.1136\/bcr-2021-245218","article-title":"Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopaenia (VITT)","volume":"14","author":"Flower","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.annemergmed.2021.12.002","article-title":"Acute ST-segment elevation myocardial infarction after ChAdOx1 nCoV-19 vaccination in a 33-year-old man","volume":"79","author":"Hsu","year":"2022","journal-title":"Ann Emerg Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/S0735-1097(22)04330-3","article-title":"Acute ST elevation myocardial infarction (MI) in young healty patient following (mRNA) COVID-19 vaccine","volume":"79","author":"Altermanini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.12865\/CHSJ.49.01.120","article-title":"ST-segment elevation acute myocardial infarction associated to COVID-19 vaccination in A healthy young adult with normal coronary arteries","volume":"49","author":"Pintos-Belotto","year":"2023","journal-title":"Curr Health Sci J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14760584.2023.2150169","article-title":"Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis","volume":"22","author":"Chang","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/IJPVM.IJPVM_260_24","article-title":"COVID-19 vaccination and cardiovascular events: a systematic review and Bayesian multivariate meta-analysis of preventive benefits and risks","volume":"16","author":"Karimi","year":"2025","journal-title":"Int J Prev Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B31","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2000"},{"key":"B32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/BMJEBM-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1038\/s41467-024-49634-x","article-title":"Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England","volume":"15","author":"Ip","year":"2024","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.vaccine.2022.05.075","article-title":"Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: a self-controlled case series study","volume":"40","author":"Ab Rahman","year":"2022","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2022.07.25.22277985","DOI":"10.1101\/2022.07.25.22277985","article-title":"Comparisons of the rate of acute myocardial infarction between COVID-19 patients and individuals received COVID-19 vaccines: a population-based study","author":"Hou","year":"2022","journal-title":"medRxiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1038\/s41467-025-61613-4","article-title":"Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study","volume":"16","author":"Pan","year":"2025","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/S13584-024-00609-9","article-title":"Pfizer COVID19 vaccine is not associated with acute cardiovascular events excluding myocarditis\u2013 a national self-controlled case series study","volume":"13","author":"Boker","year":"2024","journal-title":"Isr J Health Policy Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S1473-3099(23)00207-4","article-title":"Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study","volume":"23","author":"Yamin","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/JAMAINTERNMED.2022.2109","article-title":"Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US veterans","volume":"182","author":"Dickerman","year":"2022","journal-title":"JAMA Intern Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.7326\/M22-0988","article-title":"Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France","volume":"175","author":"Botton","year":"2022","journal-title":"Ann Intern Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/J.DSX.2021.04.006","article-title":"Myocardial infarction after COVID-19 vaccination-casual or causal?","volume":"15","author":"Chatterjee","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.amjcard.2021.06.047","article-title":"Acute myocardial infarction within 24 hours after COVID-19 vaccination","volume":"156","author":"Sung","year":"2021","journal-title":"Am J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"01","DOI":"10.3389\/FMED.2023.1071239\/PDF","article-title":"Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine","volume":"10","author":"Badar\u00f3","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/qjmed\/hcab252","article-title":"Acute myocardial infarction and myocarditis following COVID-19 vaccination","volume":"116","author":"Aye","year":"2023","journal-title":"QJM"},{"key":"B45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ihjccr.2021.05.003","article-title":"Relation between COVID-19 vaccination and myocardial infarction \u2013 casual or coincidental?","volume":"5","author":"Srinivasan","year":"2021","journal-title":"IHJ Cardiovasc Case Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.18137\/cardiometry.2022.22.143146","article-title":"Acute myocardial infarction following COVID-19 vaccination: a cause or a coincidence?","volume":"22","author":"Elheet","year":"2022","journal-title":"Cardiometry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amjcard.2021.09.032","article-title":"Acute myocardial infarction within 24 hours after COVID-19 vaccination: is kounis syndrome the culprit?","volume":"162","author":"Kounis","year":"2021","journal-title":"Am J Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/v14081644","article-title":"Myocardial infarction following COVID-19 vaccine administration: post hoc, ergo propter hoc?","volume":"14","author":"Baronti","year":"2022","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2213-2600(22)00407-6","article-title":"Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study","volume":"11","author":"Yechezkel","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e075015","DOI":"10.1136\/bmj-2023-075015","article-title":"Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"Br Med J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.2147\/IJGM.S324349","article-title":"Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database","volume":"14","author":"Kaur","year":"2021","journal-title":"Int J Gen Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14760584.2023.2260477","article-title":"Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine","volume":"22","author":"Shabu","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.870599","article-title":"Profiling COVID-19 vaccine adverse events by statistical and ontological analysis of VAERS case reports","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1038\/s41467-022-34668-w","article-title":"Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom","volume":"13","author":"Burn","year":"2022","journal-title":"Nat Commun"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1752169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:27:24Z","timestamp":1771928844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1752169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":54,"alternative-id":["10.3389\/fcvm.2026.1752169"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1752169","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1752169"}}